Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ideaya Biosciences Inc (Ideaya) is a clinical-stage precision medicine oncology company that discovers and develops targeted therapeutics for cancer treatment. The company pipeline products including IDE849 which targets small cell lung cancer and necrotizing enterocolitis; IDE034 for the treatment of non small cell lung cancer, breast cancer, ovarian cancer, head and neck small cell cancer; and colorectal cancer; IDE161 for antibody-drug conjugate combos; IDE397 targest solid tumors; and IDE892 which treats non small cell lung cancer and pancreatic ductal adenocarcinoma; among others. It operates in across the US. Ideaya is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
5000 Shoreline Court, Suite 300, South San Francisco, California, 94080
Website
www.ideayabio.com
Telephone
1 650 4436209
No of Employees
145
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IDYA (NASD)
Revenue (2024)
$218.7M
3024.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
58.6%
(2024 vs 2023)
Market Cap*
$3.5B
Net Profit Margin (2024)
XYZ
98.7%
(2024 vs 2023)
* As of and is in US$
Ideaya Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Darovasertib: Uveal Melanoma (mUM) |
| IDE849:Small Cell Lung Cancer and Necrotizing Enterocolitis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Ideaya Biosciences Inc | Novartis AG | Immatics NV | Replimune Group Inc | Varsity Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Germany | United States of America | United Kingdom |
| City | South San Francisco | Basel | Tuebingen | Woburn | Cambridge |
| State/Province | California | Basel-Stadt | Baden-Wurttemberg | Massachusetts | England |
| No. of Employees | 145 | 75,267 | 285 | 465 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yujiro S. Hata | Chief Executive Officer; Chairman; President | Executive Board | 2026 | 51 |
| Joshua Bleharski, Ph.D. | Chief Financial Officer | Senior Management | 2025 | 51 |
| Andres Ruiz Briseno | Chief Accounting Officer | Senior Management | 2025 | 40 |
| Paul A. Barsanti, Ph.D. | Chief Technology Officer | Senior Management | - | - |
| Douglas B. Snyder | Chief Legal Officer | Senior Management | 2026 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer